DYRK1A and acute myeloid leukemia: Changes in the DYRK1A expression have been analyzed in tumor samples, and as such, DYRK1A was seen to be downregulated in breast cancer [27] and in acute myeloid leukemia (AML) tissue [55], and it is upregulated in GBM [66], lung cancer [67] and head and neck squamous cell carcinoma (HNSCC) [85], as well as in PDAC [68].